Magnetar Financial LLC Has $77.04 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Magnetar Financial LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,445.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,150 shares of the biopharmaceutical company's stock after acquiring an additional 101,150 shares during the quarter. Regeneron Pharmaceuticals accounts for about 1.8% of Magnetar Financial LLC's holdings, making the stock its 7th largest position. Magnetar Financial LLC owned 0.10% of Regeneron Pharmaceuticals worth $77,038,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter worth about $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $28,000. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC raised its stake in Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Trading Up 0.4 %

REGN traded up $2.52 during midday trading on Monday, reaching $661.00. 962,350 shares of the company were exchanged, compared to its average volume of 635,787. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $72.26 billion, a P/E ratio of 17.27, a PEG ratio of 2.34 and a beta of 0.27. The stock's 50-day simple moving average is $689.43 and its 200 day simple moving average is $813.15. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.86 earnings per share. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of recent analyst reports. Canaccord Genuity Group assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. Finally, UBS Group cut Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.